An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer

Cancer Research

Volumn 74, Issue 9, 2014, Pages 2391-2401

  Araujo, Arturo ^a,b   Cook, Leah M ^b   Lynch, Conor C ^b   Basanta, David ^a  

^a Integrated Mathematical Oncology   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MATRIX; BONE METASTASIS; CANCER CELL; CANCER SURVIVAL; CELL COMPOSITION; COMPUTER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR MICROENVIRONMENT;

BONE AND BONES; BONE NEOPLASMS; CELL LINE; CELL MOVEMENT; COMPUTER SIMULATION; HUMANS; MALE; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOCLASTS; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84900001671     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2652     Document Type: Article

References (46)

1. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91:718-29.
2. Brown JE, Coleman RE. Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol 2012;9:110-8.
3. Bilezikian J, Raisz L, Martin T. Principles of Bone Biology: AcademicPress; 2008.
4. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 2008;27:41-55.
5. Lynch CC. Matrix metalloproteinases as master regulators of thevicious cycle of bone metastasis. Bone 2010;48:44-53.
6. Swanson KR, Rostomily RC, Alvord EC Jr. A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle. Br J Cancer 2008;98:113-9.
7. Anderson AR, Quaranta V. Integrative mathematical oncology. Nat RevCancer 2008;8:227-34. (Pubitemid 351301842)
8. Basanta D, Strand DW, Lukner RB, Franco OE, Cliffel DE, Ayala GE, et al. The role of transforming growth factor-beta-mediated tumorstroma interactions in prostate cancer progression: an integrative approach. Cancer Res 2009;69:7111-20.
9. Anderson ARA. A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Math Med Biol 2005;22:163-86. (Pubitemid 41511340)
10. Pfeilschifter J, Diel I, Scheppach B, Bretz A, Krempien R, Erdmann J, et al. Concentration of transforming growth factor beta in human bone tissue: relationship to age, menopause, bone turnover, and bone volume. J Bone Miner Res 1998;13:716-30. (Pubitemid 28163023)
11. Martin T, Gooi JH, Sims NA. Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr 2009;19:73-88.
12. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins 1. Growth Factors 2004;22:233-41.
13. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
14. Mundy GR. Metastasis to bone: causes, consequences and therapeuticopportunities. Nat Rev Cancer 2002;2:584-93. (Pubitemid 37328925)
15. Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 2001;16:1787-94. (Pubitemid 32911484)
16. Yasui T, Kadono Y, Nakamura M, Oshima Y, Matsumoto T, Masuda H, et al. Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J Bone Miner Res 2011;26:1447-56.
17. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994;32:73-84. (Pubitemid 24322250)
18. Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, et al. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci 2009;100:71-81.
19. Thiolloy S, Edwards JR, Fingleton B, Rifkin DB, Matrisian LM, Lynch CC. An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. PLoSONE2012;7:e29862.
20. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992;68:855.
21. Thiolloy S, Halpern J, Holt GE, Schwartz HS, Mundy GR, Matrisian LM, et al. Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res 2009;69:6747-55.
22. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005;146:1727-36. (Pubitemid 40396881)
23. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s. (Pubitemid 44703797)
24. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
25. Bonewald LF, Mundy GR. Role of transforming growth factor-beta i bone remodeling. Clin Orthop Relat Res 1990:261-76. (Pubitemid 20033993)
26. Rucci N, Teti A. Osteomimicry: how tumor cells try to deceive the bone. Front Biosci 2010;2:907-15.
27. Johnson LC, Johnson RW, Munoz SA, Mundy GR, Peterson TE, Sterling JA. Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction. Bone 2011;48:141-51.
28. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletalrelated events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082-92.
29. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-7. (Pubitemid 350013849)
30. Horn M, Glauche I, Muller MC, Hehlmann R, Hochhaus A, Loeffler M, et al. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood 2013;121:378-84.
31. Wilkinson RD. Approximate Bayesian computation (ABC) gives exact results under the assumption of model error. Stat Appl Genet Mol Biol 2013;12:129-41.
32. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. Nature 2005;435: 1267-70. (Pubitemid 40943094)
33. Murakami Y, Takada S. Bayesian parameter inference by Markov chain Monte Carlo with hybrid fitness measures: theory and test in apoptosis signal transduction network. PLoS ONE 2013;8:e74178.
34. Jayakumar P, Di Silvio L. Osteoblasts in bone tissue engineering. Proc Inst Mech Eng H 2010;224:1415-40.
35. Roodman GD. Osteoclast differentiation. Crit Rev Oral Biol Med 1991;2:389-409.
36. Ferrier J, Xia SL, Lagan E, Aubin JE, Heersche JN. Displacement and translocation of osteoblast-like cells by osteoclasts. J Bone Miner Res 1994;9:1397-405. (Pubitemid 24268851)
37. Dacquin R, Domenget C, Kumanogoh A, Kikutani H, Jurdic P, Machuca-Gayet I. Control of bone resorption by semaphorin 4D is dependent on ovarian function. PLoS ONE 2011;6:e26627.
38. Monchau F, Lefevre A, Descamps M, Belquin-myrdycz A, Laffargue P, Hildebrand HF. In vitro studies of human and rat osteoclast activity on hydroxyapatite, beta-tricalcium phosphate, calcium carbonate. Biomol Eng 2002;19:143-52.
39. Shin H, Zygourakis K, Farach-Carson MC, Yaszemski MJ, Mikos AG. Attachment, proliferation, and migration of marrow stromal osteoblasts cultured on biomimetic hydrogels modified with an osteopontin- derived peptide. Biomaterials 2004;25:895-906. (Pubitemid 37371997)
40. UBC. Diffusion rates for molecules Available from: http://www.math. ubc.ca/~ais/website/status/diffuse.html
41. Christley S, Alber MS, Newman SA. Patterns of mesenchymal condensation in a multiscale, discrete stochastic model. PLoS Comput Biol 2007;3:e76.
42. Kaminska B, Wesolowska A, Danilkiewicz M. TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol 2005;52: 329-37. (Pubitemid 41133768)
43. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest 1990;86: 1976-84.
44. Wergedal J, Stauffer M, Baylink D, Rich C. Inhibition of bone matrix formation, mineralization, and resorption in thyroparathyroidectomized rats. J Clin Invest 1973;52:1052-8.
45. Kanehisa J, Heersche JN. Osteoclastic bone resorption: in vitro analysis of the rate of resorption and migration of individual osteoclasts. Bone 1988;9:73-9.
46. Bloebaum RD, Bachus KN, Momberger NG, Hofmann AA. Mineral apposition rates of human cancellous bone at the interface of porous coated implants. J Biomed Mater Res 1994;28:537-44. (Pubitemid 24132523)